Randy Osborne

Corixa, GSK Changing Terms Of Cancer Vaccine Agreement

Jan. 31, 2003

By Randy Osborne

Genome Therapeutics, MerLion In Antibacterials Discovery Deal

Jan. 29, 2003

By Randy Osborne

Onyx Stopping One Phase III, Restructuring To Push Another

Jan. 28, 2003

By Randy Osborne

NaPro Buys Pangene System For Genomics Tools Arsenal

Jan. 28, 2003

By Randy Osborne

GSK, ImmunoGen Ending Deal To Develop TAP Cancer Drug

Jan. 27, 2003

By Randy Osborne

Unable to find a retooled deal pleasing to both sides, ImmunoGen Inc. and GlaxoSmithKline plc - which earlier said they were striving to do so - have ended their development agreement for cantuzumab mertansine (huC242-DM1). (BioWorld Today)

Avant: Case Study Of A Defense Deal Helping Keep Firms Healthy

Jan. 27, 2003

By Randy Osborne

Some cynical Europeans might snicker about industry in America profiting from a threatened terrorist siege. Other commentators may marvel instead at company scientists' ability to engineer biodefense weapons. The editorial-page beat goes on.

Geron Reducing Staff Again To Push Lead Cancer Drug

Jan. 23, 2003

By Randy Osborne

Anthrax/Plague Vaccine Funds Will Help Avant With Pipeline

Jan. 23, 2003

By Randy Osborne

Variagenics Turns Away Acacia, Moves Ahead With Hyseq Deal

Jan. 22, 2003

By Randy Osborne

Spurning an eleventh-hour suitor that made an offer last week, diagnostic testing firm Variagenics Inc. said its board wants to go ahead with the previously planned merger with Hyseq Inc. (BioWorld Today)